GlassScriptPhysician profile
Michael J Sojka
NPI 1306339908
$3,990.59
in general payments reported to CMS, 2019-2025
37 companies · $1,533 in 2025
The $1,533 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $197 · 2021: $155 · 2022: $402 · 2023: $882 · 2024: $662 · 2025: $1,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $526.33 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $507.88 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $352.30 | 2019-2023 | Spravato |
| Abbvie INC. | $345.01 | 2022-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $280.34 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $217.46 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $174.99 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.12 | 2022-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Astrazeneca Pharmaceuticals LP | $145.14 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $121.22 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $113.22 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $107.22 | 2022-2025 | Azstarys |
| Amgen INC. | $104.64 | 2022-2025 | Repatha, Otezla, Otezla |
| Lundbeck LLC | $86.64 | 2025 | Vyepti |
| Gilead Sciences, INC. | $79.63 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $63.51 | 2024-2025 | Voquezna |
| Sonex Health, INC. | $54.20 | 2025 | Sx-One Microknife |
| Takeda Pharmaceuticals U.S.A., INC. | $52.23 | 2021-2025 | Trintellix |
| Baxter Healthcare | $52.19 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Tolmar, INC. | $48.88 | 2025 | Jatenzo |
| Sumitomo Pharma America, INC. | $40.12 | 2025 | Gemtesa |
| Impel Pharmaceuticals LLC | $36.89 | 2025 | Trudhesa |
| Alkermes, INC. | $31.13 | 2023-2024 | Vivitrol, Vivitrol |
| Paratek Pharmaceuticals, INC. | $28.48 | 2024-2025 | Nuzyra |
| Ars Pharmaceuticals Operations, INC. | $23.76 | 2025 | Neffy |
| Inogen, INC. | $23.72 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Amneal Pharmaceuticals LLC | $23.40 | 2024 | Unithroid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.92 | 2025 | Caplyta |
| Abbott Laboratories | $22.51 | 2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $22.45 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $19.69 | 2022 | |
| Inari Medical, INC. | $17.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.68 | 2022 | |
| Dexcom, INC. | $15.55 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2024 | Xifaxan |
| Ibsa Pharma INC. | $14.66 | 2023 | Tirosint, Licart |
| Bayer Healthcare Pharmaceuticals INC. | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sojka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.